Doğan E - Search Results

1

Ipilimumab-associated cholestatic hepatitis: a case report and literature review.

Yildirim S, Deniz K, Doğan E, Başkol M, Gürsoy Ş, Özkan M. Yildirim S, et al. Among authors: dogan e. Melanoma Res. 2017 Aug;27(4):380-382. doi: 10.1097/CMR.0000000000000366. Melanoma Res. 2017. PMID: 28489679 Review.

2

Biweekly cisplatin and gemcitabine with two different doses in non small cell lung cancer patients: A retrospective singlecenter experience.

Dogan E, Ucar M, Sakalar T, Derin S, Bozkurt O, Inanc M, Ozkan M. Dogan E, et al. J BUON. 2018 Jul-Aug;23(4):1070-1076. J BUON. 2018. PMID: 30358213 Free article.

3

Efficacy of second-line targeted agents in kras wild metastatic colorectal cancer patients who received prior targeted agent: First anti-epidermal growth factor receptor or vascular endothelial growth factor in right and left colon?

Dogan E, Firat ST, Cosar R, Bozkurt O, Inanc M, Ozkan M. Dogan E, et al. J Oncol Pharm Pract. 2020 Jun;26(4):781-786. doi: 10.1177/1078155219856682. Epub 2019 Jun 25. J Oncol Pharm Pract. 2020. PMID: 31238809

4

Impact of neutrophil-lymphocyte and platelet-lymphocyte ratio on antiEGFR and bevacizumab efficacy in metastatic colorectal cancer.

Dogan E, Bozkurt O, Sakalar T, Derin S, Inanc M, Ozkan M. Dogan E, et al. J BUON. 2019 Sep-Oct;24(5):1861-1869. J BUON. 2019. PMID: 31786848 Free article.

5

The prognostic value of the change in neutrophil-to-lymphocyte ratio during first-line palliative chemotherapy in patients with metastatic gastric cancer: A retrospective study.

Bozkurt O, Firat ST, Dogan E, Cosar R, Inanc M, Ozkan M. Bozkurt O, et al. Among authors: dogan e. J BUON. 2019 Sep-Oct;24(5):1992-1999. J BUON. 2019. PMID: 31786866 Free article.

6

Prognostic Significance of Tumor Tissue NeuGcGM3 Ganglioside Expression in Patients Receiving Racotumomab Immunotherapy.

Uskent N, Ayla S, Molinas Mandel N, Ozkan M, Teomete M, Baloglu H, Aydıncer C, Yergok H, Dogan E, Berk B, Yazar A. Uskent N, et al. Among authors: dogan e. J Oncol. 2020 Jun 29;2020:1360431. doi: 10.1155/2020/1360431. eCollection 2020. J Oncol. 2020. PMID: 32670370 Free PMC article.

7

Is SUVmax of ¹⁸F-FDG PET/CT Predictive Factor for Malignancy in Gastrointestinal Tract?

Ozaslan E, Kiziltepe M, Addulrezzak U, Kula M, Bozkurt O, Kut E, Duran AO, Ucar M, Sakalar T, Dogan E, Topaloglu US, Inanc M, Ozkan M. Ozaslan E, et al. Among authors: dogan e. Niger J Clin Pract. 2021 Aug;24(8):1217-1224. doi: 10.4103/njcp.njcp_637_18. Niger J Clin Pract. 2021. PMID: 34397034

8

Pure mucinous carcinoma of the breast: a single center experience.

Dogan E, Aksoy S, Dizdar O, Arslan C, Dede DS, Ozisik Y, Altundag K. Dogan E, et al. J BUON. 2011 Jul-Sep;16(3):565-7. J BUON. 2011. PMID: 22006768

9

Secondary hematological malignancies after treatment of non-metastatic breast cancer.

Arslan C, Ozdemir E, Dogan E, Ozisik Y, Altundag K. Arslan C, et al. Among authors: dogan e. J BUON. 2011 Oct-Dec;16(4):744-50. J BUON. 2011. PMID: 22331732

10

A modified DCF regimen as primary treatment for patients with metastatic gastric cancer.

Koca D, Dogan E, Yardim H, Duzen O, Karaca S. Koca D, et al. Among authors: dogan e. J BUON. 2013 Apr-Jun;18(2):377-84. J BUON. 2013. PMID: 23818349 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

515 results

Search Page

Filters